Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
New England Journal of Medicine · 29.01.2026 · 394 (5) · 451-462
DOI: 10.1056/nejmoa2511218 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 29.01.2026. Verfasst von Otto Metzger und 38 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Piperazines. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Pfizer Foundation, Breast Cancer Trials, Alliance Foundation Trials.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Harvard Medical School, Boston.
- Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN.
- Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
- Institut Universitaire de Cancérologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Tenon Hospital and INSERM Unité 938, Paris.
- Unicancer Breast Group, Paris.
- Garvan Institute of Medical Research, Sydney.
ORCID-Profile: Lisa A Carey
Förderung
- Pfizer Foundation
- Breast Cancer Trials
- Alliance Foundation Trials
- German Breast Group
- Fondazione Michelangelo
- SOLTI
- PrECOG
- Unicancer
Zitieren
APA
Metzger, O., Mandrekar, S., Goel, S., Gligorov, J., Lim, E., Ciruelos, E., Loibl, S., Dockter, T., Gonzàlez Farré, X., Francis, P. A., Lynce, F., Lanzillotti, J., DuFrane, C., Wall, A., Strand, C., Krop, I., Vaz-Luis, I., Tripathy, D., Loi, S., …, & Carey, L. A. (2026). Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer. New England Journal of Medicine, 394(5), 451-462. https://doi.org/10.1056/nejmoa2511218
Vancouver
Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, et al. Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 2026;394(5):451-462. doi:10.1056/nejmoa2511218
BibTeX
@article{Metzger2026,
author = {Metzger, Otto and Mandrekar, Sumithra and Goel, Shom and Gligorov, Joseph and Lim, Elgene and Ciruelos, Eva and Loibl, Sibylle and Dockter, Travis and Gonzàlez Farré, Xavier and Francis, Prudence A and Lynce, Filipa and Lanzillotti, Jane and DuFrane, Carter and Wall, Anna and Strand, Carrie and Krop, Ian and Vaz-Luis, Ines and Tripathy, Debu and Loi, Sherene and Prat, Aleix and Goetz, Matthew and Escrivá-de-Romaní, Santiago and Porter, David and Spoenlein, Jennifer and Stover, Daniel G and Sardesai, Sagar and Heudel, Pierre and Koehler, Maria and Huang Bartlett, Cynthia and Holynskyj, Ariadna and Gopalakrishna, Prashanth and Gauthier, Eric and Delaloge, Suzette and Miller, Kathy and Winer, Eric P and Gianni, Luca and Partridge, Ann H and DeMichele, Angela and Carey, Lisa A},
title = {Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {5},
pages = {451--462},
doi = {10.1056/nejmoa2511218}
}
EUVIMED